- Home
- SWAG vs BCAB Comparison
SWAG vs BCAB Comparison
Compare SWAG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWAG
- BCAB
- Stock Information
- Founded
- SWAG 1994
- BCAB 2007
- Country
- SWAG United States
- BCAB United States
- Employees
- SWAG N/A
- BCAB N/A
- Industry
- SWAG Advertising
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- SWAG Consumer Discretionary
- BCAB Health Care
- Exchange
- SWAG Nasdaq
- BCAB Nasdaq
- Market Cap
- SWAG 30.4M
- BCAB 31.5M
- IPO Year
- SWAG 2021
- BCAB 2020
- Fundamental
- Price
- SWAG $1.85
- BCAB $0.67
- Analyst Decision
- SWAG
- BCAB Hold
- Analyst Count
- SWAG 0
- BCAB 3
- Target Price
- SWAG N/A
- BCAB $1.00
- AVG Volume (30 Days)
- SWAG 207.0K
- BCAB 905.7K
- Earning Date
- SWAG 11-06-2025
- BCAB 11-06-2025
- Dividend Yield
- SWAG N/A
- BCAB N/A
- EPS Growth
- SWAG N/A
- BCAB N/A
- EPS
- SWAG N/A
- BCAB N/A
- Revenue
- SWAG $108,405,000.00
- BCAB $11,000,000.00
- Revenue This Year
- SWAG N/A
- BCAB N/A
- Revenue Next Year
- SWAG N/A
- BCAB N/A
- P/E Ratio
- SWAG N/A
- BCAB N/A
- Revenue Growth
- SWAG 38.74
- BCAB N/A
- 52 Week Low
- SWAG $0.73
- BCAB $0.24
- 52 Week High
- SWAG $1.93
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- SWAG 62.46
- BCAB 75.13
- Support Level
- SWAG $1.72
- BCAB $0.44
- Resistance Level
- SWAG $1.84
- BCAB $0.46
- Average True Range (ATR)
- SWAG 0.11
- BCAB 0.06
- MACD
- SWAG 0.01
- BCAB 0.03
- Stochastic Oscillator
- SWAG 75.68
- BCAB 81.63
About SWAG Stran & Company Inc.
Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.